Edition:
United States

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

1.00USD
21 Feb 2018
Change (% chg)

$-0.01 (-0.99%)
Prev Close
$1.01
Open
$1.00
Day's High
$1.00
Day's Low
$1.00
Volume
36,011
Avg. Vol
71,406
52-wk High
$1.34
52-wk Low
$0.80

Chart for

About

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 187.16 16.73
EPS (TTM): -- -- --
ROI: -- -0.71 35.60
ROE: -- -3.52 17.23

BRIEF-Biolinerx Announces Partial Monotherapy Results From Phase 2A Combat Study In Pancreatic Cancer

* BIOLINERX ANNOUNCES PARTIAL MONOTHERAPY RESULTS FROM PHASE 2A COMBAT STUDY IN PANCREATIC CANCER

Jan 17 2018

BRIEF-Bioline Rx Ltd Files For Mixed Shelf Of Up To $150 Million

* BIOLINE RX LTD FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text (http://bit.ly/2lcDvcH) Further company coverage:

Dec 28 2017

InVivo to open crop input unit to outside investors

PARIS, Dec 19 French agricultural group InVivo said on Tuesday that it plans to raise 50 million euros ($59 million) for its Bioline division, which develops crop inputs such as seeds and pesticides, by bringing in outside investors.

Dec 19 2017

BRIEF-BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML

* BIOLINERX REPORTS OVERALL SURVIVAL RESULTS FROM LONG-TERM FOLLOW-UP OF PHASE 2A TRIAL IN R/R AML

Dec 04 2017

BRIEF-BioLine Rx Ltd Q3 ‍loss per ordinary share $0.07​

* BioLine Rx ltd - qtrly ‍loss per ordinary share $0.07​ Source text for Eikon: Further company coverage:

Nov 21 2017

BRIEF-BioLineRX initiates phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration

* BioLineRX announces initiation of phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration

Oct 18 2017

BRIEF-BioLineRx announces initiation of Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration

* BioLineRx announces initiation of Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration Source text for Eikon: Further company coverage:

Sep 26 2017

Earnings vs. Estimates